Last reviewed · How we verify
Enbrel (etanercept)
Etanercept is a fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine, thereby reducing inflammation and immune activation.
Etanercept is a fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine, thereby reducing inflammation and immune activation. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Enbrel (etanercept) |
|---|---|
| Also known as | Enbrel |
| Sponsor | Pfizer |
| Drug class | TNF inhibitor (TNF receptor fusion protein) |
| Target | TNF-alpha (TNF) and TNF-beta (lymphotoxin-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Etanercept is a recombinant TNF receptor p75-IgG1 Fc fusion protein that acts as a soluble TNF receptor. It binds circulating TNF-alpha and TNF-beta with high affinity, preventing their interaction with cell-surface TNF receptors and thereby suppressing the inflammatory cascade. This TNF inhibition reduces joint inflammation, systemic inflammation, and immune-mediated tissue damage in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Polyarticular juvenile idiopathic arthritis
- Plaque psoriasis
- Crohn's disease
Common side effects
- Injection site reactions (erythema, itching, pain)
- Upper respiratory tract infections
- Headache
- Serious infections (including tuberculosis, sepsis)
- Demyelinating disease
- Congestive heart failure exacerbation
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (PHASE2, PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- Psoriasis Longitudinal Assessment and Registry
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PHASE3)
- TNF-α Treatment of Blast-Induced Tinnitus (PHASE2)
- Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enbrel (etanercept) CI brief — competitive landscape report
- Enbrel (etanercept) updates RSS · CI watch RSS
- Pfizer portfolio CI